Literature DB >> 18694380

Akt as a therapeutic target in cancer.

Linda S Steelman1, Kristin M Stadelman, William H Chappell, Stefan Horn, Jörg Bäsecke, Melchiorre Cervello, Ferdinando Nicoletti, Massimo Libra, Franca Stivala, Alberto M Martelli, James A McCubrey.   

Abstract

BACKGROUND: The phosphatidylinositol 3-kinase (PI3K)/phosphatase and tensin homolog (PTEN)/v-akt murine thymoma viral oncogene homolog (Akt)/mammalian target of rapamycin (mTOR) pathway is central in the transmission of growth regulatory signals originating from cell surface receptors.
OBJECTIVE: This review discusses how mutations occur that result in elevated expression the PI3K/PTEN/Akt/mTOR pathway and lead to malignant transformation, and how effective targeting of this pathway may result in suppression of abnormal growth of cancer cells.
METHODS: We searched the literature for articles which dealt with altered expression of this pathway in various cancers including: hematopoietic, melanoma, non-small cell lung, pancreatic, endometrial and ovarian, breast, prostate and hepatocellular. RESULTS/
CONCLUSIONS: The PI3K/PTEN/Akt/mTOR pathway is frequently aberrantly regulated in various cancers and targeting this pathway with small molecule inhibitors and may result in novel, more effective anticancer therapies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18694380     DOI: 10.1517/14728222.12.9.1139

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  60 in total

1.  Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.

Authors:  Li-E Wang; Hongxia Ma; Katherine S Hale; Ming Yin; Larissa A Meyer; Hongliang Liu; Jie Li; Karen H Lu; Bryan T Hennessy; Xuesong Li; Margaret R Spitz; Qingyi Wei; Gordon B Mills
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-07       Impact factor: 4.553

2.  Increased activation of the PI3K/AKT pathway compromises decidualization of stromal cells from endometriosis.

Authors:  Xunqin Yin; Mary Ellen Pavone; Zhenxiao Lu; JianJun Wei; J Julie Kim
Journal:  J Clin Endocrinol Metab       Date:  2011-11-09       Impact factor: 5.958

3.  The effect of a novel frizzled 8-related antiproliferative factor on in vitro carcinoma and melanoma cell proliferation and invasion.

Authors:  Kristopher R Koch; Chen-Ou Zhang; Piotr Kaczmarek; Joseph Barchi; Li Guo; Hanief M Shahjee; Susan Keay
Journal:  Invest New Drugs       Date:  2011-09-20       Impact factor: 3.850

Review 4.  Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells.

Authors:  Shanchun Guo; Mingli Liu; Guangdi Wang; Marta Torroella-Kouri; Ruben R Gonzalez-Perez
Journal:  Biochim Biophys Acta       Date:  2012-01-24

5.  PKR regulates B56(alpha)-mediated BCL2 phosphatase activity in acute lymphoblastic leukemia-derived REH cells.

Authors:  Vivian R Ruvolo; Svitlana M Kurinna; Kul B Karanjeet; Todd F Schuster; Alberto M Martelli; James A McCubrey; Peter P Ruvolo
Journal:  J Biol Chem       Date:  2008-10-28       Impact factor: 5.157

6.  Mechanistic Study of Inhibitory Effects of Atorvastatin and Docetaxel in Combination on Prostate Cancer.

Authors:  Xuan Chen; Yue Liu; Jian Wu; Huarong Huang; Zhiyun Du; Kun Zhang; Daiying Zhou; Kaylyn Hung; Susan Goodin; Xi Zheng
Journal:  Cancer Genomics Proteomics       Date:  2016 Mar-Apr       Impact factor: 4.069

Review 7.  Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells.

Authors:  James A McCubrey; Stephen L Abrams; Kristin Stadelman; William H Chappell; Michelle Lahair; Richard A Ferland; Linda S Steelman
Journal:  Adv Enzyme Regul       Date:  2009-11-04

8.  Akt as a victim, villain and potential hero in Parkinson's disease pathophysiology and treatment.

Authors:  Lloyd A Greene; Oren Levy; Cristina Malagelada
Journal:  Cell Mol Neurobiol       Date:  2011-03-10       Impact factor: 5.046

9.  Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience.

Authors:  John Moroney; Jennifer Wheler; David Hong; Aung Naing; Gerald Falchook; Diane Bodurka; Robert Coleman; Karen Lu; Lianchun Xiao; Razelle Kurzrock
Journal:  Gynecol Oncol       Date:  2010-03-26       Impact factor: 5.482

Review 10.  Potential role of sorafenib in the treatment of acute myeloid leukemia.

Authors:  Shahram Mori; Jorge Cortes; Hagop Kantarjian; Weiguo Zhang; Michael Andreef; Farhad Ravandi
Journal:  Leuk Lymphoma       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.